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Abstract
By attaching multiple copies of the influenza M2 ion channel inhibitors amantadine (1) and
rimantadine (2) to polymeric chains we endeavored to recover their potency in inhibiting drug-
resistant influenza viruses. Depending on loading densities, as well as the nature of the drug, the
polymer, and the spacer arm, polymer-conjugated drugs were up to 30-fold more potent inhibitors
of drug-resistant strains than their monomeric parents. In particular, a 20% loading density and a
short linker group on the negatively charged poly-L-glutamate resulted in some of the most potent
inhibitors for 2′s conjugates against drug-resistant influenza strains. Although full recovery of the
inhibitory action against drug-resistant strains was not achieved, this study may be a step toward
salvaging anti-influenza drugs that are no longer effective.
Introduction
Influenza viruses are a commonly infect the respiratory tract in humans1 and are a major
cause of morbidity and mortality in the world.2,3 Two of the four FDA-approved small-
molecule anti-influenza drugs — the adamantane-class M2 ion-channel inhibitors
amantadine (1) and rimantadine (2) (Fig. 1) — are no longer recommended as therapeutics
because nearly every circulating influenza A strain has evolved resistance to them.2,4,5
These drugs block the M2 ion channels on the surface of the virus,6-9 thereby preventing the
flow of protons into the viral core (an essential step in the viral infection cycle).2 Resistance
to 1 and 2 is due to point mutations in the M2 ion channel protein, with the most common
being the S31N in the interior of the channel.2
Because of the daunting challenges in discovering new anti-influenza drugs, it would be of
great benefit to salvage older FDA-approved drugs that are impotent against newly emerged
mutants. Previously, we have demonstrated that the attachment of multiple copies of the
influenza neuraminidase inhibitor zanamivir to a flexible polymeric chain not only
dramatically improves the potency against drug-sensitive strains, but also resurrects the
inhibitory effect against zanamivir-resistant mutants.10,11 This phenomenon appears to stem
from two mechanisms. The first is multivalency, whereby several simultaneous interactions
between polymer-attached zanamivir and its viral target result in a far greater avidity
compared to the monomer's binding constant,10,12,13 while also generating an increased drug
concentration in the vicinity of the virus.13 The second contributor to the improved potency
is a novel mechanism of inhibition, blocking earlier stages of the viral cycle, which
monomeric zanamivir lacks.3 Herein we explore whether the approach of attaching multiple
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copies of influenza drugs to polymeric chains can boost the adamantane inhibitors' prowess
against drug-resistant influenza mutants (as it did with zanamivir10).
Materials and Methods
Materials
Amantadine·HCl (1; here and henceforth the bold number equally applies to a free base/acid
and its salt), rimantadine·HCl (2), 3-amino-1-adamantanecarboxylic acid (3), 3-(1-
aminoethyl)adamantan-1-ol·HCl (7), poly-L-glutamate Na salt (MW of 50-100 kDa),
carboxymethylcellulose Na salt (MW of ∼100 kDa) (CMC), poly(acrylic acid) (MW of
∼100 kDa), and all solvents and other reagents were purchased from Sigma Aldrich
Chemical Co. (St. Louis, MO) and used without further purification unless otherwise
specified. N-Hydroxysulfosuccinimide (sulfo-NHS) was from Proteochem (Denver, CO), 5-
azidopentanoic acid and 5-azidopentan-1-amine from Synthonix (Wake Forest, NC), and 11-
azido-3,6,9-trioxaundecanoic acid from TCI America (Portland, OR).
Syntheses
Synthesis of 1-linker-azide (6)—Linker addition to 3 was carried out as described by
Wanka et al.14 Briefly, 300 mg (1.5 mmol) of 3 and 715 mg (6.7 mmol) of Na2CO3 were
suspended in a mixture of 10 mL of H2O and 5 mL of acetone, followed by stirring and
placing in an ice bath. Next, Fmoc-Cl (426 mg, 1.6 mmol) in 5 mL of acetone was added
over 30 min with an addition funnel. The reaction mixture was incubated at room
temperature (RT) overnight and then heated to 50°C for 2 h to evaporate acetone. To purify
the product, the reaction was poured over ice (35 grams) and extracted thrice with diethyl
ether. The aqueous layer was then acidified to pH 5 and extracted thrice with ethyl acetate.
The ethyl acetate portions were combined, washed with H2O, and dried over Na2SO4 to
afford an off-white powder of Fmoc-3-amino-1-adamantanecarboxylic acid (4) (∼40%
yield). Rf on TLC silica plate of 0.47 in 10:1 (v/v) CH2Cl2:MeOH. 1H NMR 4 ([D8]THF) δ
(400 MHz): 1.65 (2H, d, CH2-1), 1.72 (2H, s, CH2-1), 1.83 (4H, s, CH2-1), 1.95 (4H, s,
CH2-1), 2.07 (H, s, CH-1), 2.14 (H, s, CH-1), 4.18 (1H, t, CH-Fmoc), 4.27 (2H, d, CH2-
Fmoc), 7.25 (2H, t, CH-aromatic-Fmoc), 7.3 (2H, t, CH-aromatic-Fmoc), 7.6 (2H, d, CH-
aromatic-Fmoc), 7.8 (2H, d, CH-aromatic-Fmoc).
To synthesize 5, 4 (220 mg, 0.53 mmol) was dissolved in 5 mL of dry THF. To that, O-
benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (200 mg,
0.53 mmol) was added, followed by 65 μL (0.53 mmol) of 5-azidopentan-1-amine and 68
μL (0.5 mmol) of Hünig's base. The reaction mixture was stirred at RT overnight and then
heated to 60°C for 1 h. After cooling, 3 mL of brine was added, and the mixture was
extracted with CHCl3 thrice. The organic phases were combined, washed with 1 M HCl, 5%
NaHCO3, H2O, and brine, and then further purified on a silica gel column with 10:1 (v/v)
CH2Cl2:methanol mobile phase to afford 514 (∼55% yield). Rf on TLC silica plate of 0.82 in
10:1 (v/v) CH2Cl2:MeOH.1H NMR 5 (CDCl3) δ (400 MHz): 1.35 (2H, m, CH2-linker),
1.47(2H, m, CH2-linker), 1.6 (4H, m, CH2-1, CH2-linker), 1.78 (4H, s, CH2-1), 1.85 (2H, d,
CH2-1), 1.95 (2H, d, CH2-1), 2.05 (2H, s, CH2-1), 2.18 (2H, s, CH-1), 3.2 (2H, dd, CH2-
linker), 3.24 (2H, t, CH2-linker), 4.18 (1H, t, CH-Fmoc), 4.3 (2H, d, CH2-Fmoc), 7.25 (2H,
t, CH-aromatic-Fmoc), 7.3 (2H, t, CH-aromatic-Fmoc), 7.6 (2H, d, CH-aromatic-Fmoc), 7.7
(2H, d, CH-aromatic-Fmoc).
To generate the deprotected final 1-linker-azide (6) for attachment to poly-L-glutamate, 5
(75 mg, 0.14mmol) was dissolved in 1.2 mL of dry acetonitrile and cooled to 0°C.
Diethylamine (1.2 mL) was added, and the reaction mixture was stirred for 1 h at 0°C and
RT for 24 h. The reaction mixture was then extracted with H2O at pH 3, and the product (6)
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was recovered from the aqueous phase14 (∼20% yield). Rf on TLC silica plate of 0.12 in
10:1 (v/v) CH2Cl2:MeOH.1H NMR 6 (CDCl3) δ (400 MHz): 1.27 (2H, m, CH2-linker),
1.45(2H, m, CH2-linker), 1.52 (2H, m, CH2-linker), 1.61 (2H, s, CH2-1), 1.7 (2H, d, CH2-1),
1.78 (4H, d, CH2-1), 1.83 (2H, d, CH2-1), 1.88 (2H, s, CH2-1), 3.1 (2H, t, CH2-linker), 2.25
(2H, s, CH-1), 3.25 (2H, t, CH2-linker).
Synthesis of 2-linker-azides (11 and 12)—To obtain an organic solvent soluble free
base, 3-(1-aminoethyl)adamantan-1-ol·HCl was suspended in CH2Cl2 and washed with 1 M
NaOH . The resultant organic layer was rotary-evaporated, and the isolated white powder of
3-(1-aminoethyl)adamantan-1-ol (7) was Boc-protected for subsequent chemical
modification. To this end, a solution of di-tert-butyl dicarbonate (327 mg, 1.5 mmol) in 25
mL of CH2Cl2 was added to 5 mL of CH2Cl2-containing 7 (292 mg, 1.4 mmol). The
reaction mixture was stirred at RT for 24 h after which it was extracted thrice with saturated
Na2CO3 and dried over Na2SO4 to afford a white fluffy powder of 815 (∼95% yield). Rf on
TLC silica plate of 0.63 in 10:1 (v/v) CH2Cl2:MeOH. 1H NMR 8 (CDCl3) δ (400 MHz):
0.98 (3H, d, CH3-2), 1.33 (2H, d, CH2-2), 1.39 (11H, s, Boc, CH2-2), 1.47 (2H, s, CH2-2),
1.57 (2H, d, CH2-2), 1.62 (2H, d, CH2-2), 1.75 (1H, s, CH-2), 2.15(2H, s, CH2-2), 3.4 (1H,
m, CH-2), 4.4 (1H, m, CH-2).
Next, the Boc-protected 3-(1-aminoethyl)adamantan-1-ol (8) was reacted with 5-
azidopentanoic acid in a method similar to that of Saitoh et al.16 Briefly, 8 (134 mg, 0.5
mmol), 5-azidopentanoic acid (128 μL, 1.0 mmol), and 4-dimethylaminopyridine (DMAP)
(6 mg, 0.03mmol) were dissolved in 3 mL of chlorobenzene. To that mixture, di(2-
pyridyl)thionocarbonate (DPTC) (230 mg, 1.0 mmol) was added, and the reaction mixture
was refluxed for 1 h, concentrated, and purified on a silica gel column with 2:1 (v/v)
hexane:ethyl acetate mobile phase to afford 9 (∼55% yield). Rf on TLC silica plate of 0.54
in 2:1 (v/v) hexane:ethyl acetate. To prepare 10, 11-azido-3,6,9-trioxaundecanoic acid was
used in place of 5-azidopentanoic acid and the reaction mixture was purified on a silica gel
column with 7:1 (v/v) CHCl3:acetone as a mobile phase (∼65% yield). Rf on TLC silica
plate of 0.60 in 7:1 (v/v) CHCl3:acetone. 1H NMR 9 (CDCl3) δ (400 MHz): 0.98 (3H, d,
CH3-2), 1.35 (11H, s, Boc, CH2-2), 1.45 (2H, d, CH2-2), 1.57 (4H, m, CH2-linker), 1.75
(2H, m, CH2-2), 1.95 (3H, m, CH2-2, CH-2), 2.05 (2H, d, CH2-2), 2.2 (4H, m, CH2-2, CH2-
linker), 3.22 (2H, m, CH2-linker), 3.4 (1H, m, CH-2), 4.35 (1H, m, CH-2). 1H NMR 10
(CDCl3) δ (400 MHz): 0.95 (3H, d, CH3-2), 1.35 (11H, s, Boc, CH2-2), 1.43 (2H, d,
CH2-2), 1.54 (2H, d, CH2-2), 1.78 (2H, m, CH2-2), 1.93 (2H, d, CH2-2), 2.03 (2H, d,
CH2-2), 2.09 (1H, s, CH-2), 2.17 (2H, s, CH2-2), 3.3 (2H, t, CH2-linker), 3.6 (11, m, CH2-
linker, CH-2), 3.93 (2H, s, CH2-linker), 4.35 (1H, m, CH-2).
Deprotection of the Boc group was performed with 4 M HCl in dioxane, as described
previously,17 to yield the final 2-linker-azide conjugates (11 and 12) (∼90% yield). Rf on
TLC silica plate of 0 in 2:1 (v/v) hexane:ethyl acetate. 1H NMR 11 (CDCl3) δ (400 MHz):
1.2 (3H, d, CH3-2), 1.5 (8H, m, CH2-2, CH2-linker), 1.65 (1H, d, CH-2), 1.75 (4H, s,
CH2-2), 2.05 (2H, s, CH2-2), 2.15 (2H, t, CH2-linker), 2.2 (2H, s, CH2-2), 2.95 (1H, t,
CH-2), 3.2 (2H, t, CH2-linker), 4.3 (1H, d, CH-2). 1H NMR 12 (CDCl3) δ (400 MHz): 1.3
(3H, d, CH3-2), 1.5 (2H, d, CH2-2), 1.6 (2H, s, CH2-2), 1.72 (1H, d, CH-2), 1.92 (4H, m,
CH2-2), 2.1 (2H, d, CH2-2), 2.25 (2H, s, CH2-2), 3.0 (1H, s, CH-2), 3.33 (2H, t, CH2-
linker), 3.62 (11H, s, CH2-linker, CH-2), 3.95 (2H, s, CH2-linker).
Because of the more facile nature and higher yields of the 2-linker-azide synthesis, we
utilized 2 for our extensive structure-activity relationship of the drug-polymer conjugates.
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Polymer activation—Polymers were activated with propargylamine to incorporate a
terminal alkyne for subsequent conjugation reactions with the aforementioned azide-
containing inhibitors 6, 11, and 12. As a representative example, poly-L-glutamate Na salt
(100 mg) was dissolved in 30 mL of H2O. To that was added 300 mg of 4-(4,6-
dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) (1.1 mmol) and 7
μL (0.15 mmol) of propargylamine to afford a ∼10% derivatized polymer. The reaction
mixture was stirred for 5 h and purified as described previously.18,19 The amount of
propargyl amine was varied to tune the % of derivatization of the polymer used. The % of
derivatization was verified by 1H NMR where the integration of one propargylamine H peak
(the alkyne singlet hydrogen) was compared to that of the integration of one known polymer
H peak (the singlet hydrogen from the poly-L-glutamate backbone).
For compounds 21 and 22, poly-L-glutamate was reacted as described above with
propargylamine and approximately 0.2 mol-eq. of either benzylamine or 2,2-dimethyl-1-
propanime, respectively.
To generate a poly-L-glutamine backbone for compound 23, the purified polymer pre-
derivatized to have ∼20% of its monomeric units activated with propargylamine was
dissolved at 10 mg/mL in 0.1 M 2-N-morpholinoethanesulfonate (MES) buffer, pH 6,
containing 0.5 M NaCl. To that mixture was added 1.2 mol-eq. of both 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide and sulfo-NHS. The reaction mixture was stirred for 30
min at RT, after which an excess of saturated aqueous NH4OH was added. Following an
overnight incubation, the product was purified for subsequent small molecule
derivatization.18
Polymer conjugation—Once the propargylamine-derivatized polymers were purified and
quantified, they were reacted in a Cu+-catalyzed [3+2] azide-alkyne cycloaddition with the
azide containing amantadine or rimantadine derivatives (6, 11, and 12) as previously
described.18 1′s or 2′s % of derivatization for each polymer-conjugate was determined
by 1H NMR by comparing the integrated peak for the newly formed triazole hydrogen to
that for the singlet hydrogen from the poly-L-glutamate backbone. An example 1H NMR
breakdown is described. 1H NMR 16 (D2O) δ (600 MHz): 1.2 (3H, d, CH3-2), 1.5 (8H, s,
CH2-2, CH2-linker), 2.0 (2H, m, CH2-polymer, 8H CH2-2, CH-2), 2.3 (2H, s, CH2-polymer,
4H, s, CH2-2, CH2-linker), 3.1 (1H, s, CH-2), 4.3 (1H, s, CH-polymer, 4H, d, CH2-2, CH2-
propargylamine), 8.0 (1H, s, CH-triazole). Efficiency for the azide-alkyne cycloaddition
ranged from approximately 70% to 100% for the small molecules. Representative 1H NMR
spectra are presented in the supporting information (Figures S1-S4).
Cells, viruses, and antiviral assays—Madin-Darby canine kidney (MDCK) cells for
use in plaque reduction assays were from the American Type Culture Collection and
maintained as described previously.11,20 The human wild-type influenza strains A/Wuhan/
359/95 (H3N2) and A/PR/8/34 (H1N1) were obtained from the U.S. Centers for Disease
Control and Prevention (Atlanta, GA) and Charles River Laboratories (North Franklin, CT),
respectively. The influenza strain A/WSN/33 (H1N1) was a gift from Dr. Peter Palese of
Mount Sinai School of Medicine (NY, NY). Viruses were stored in a −80°C freezer and
diluted in phosphate-buffered saline (PBS) for use in assays.
Plaque reduction assays with MDCK cells were carried out to determine the half-maximal
inhibitory concentration (IC50) of both monomeric and polymer-attached compounds as
described before.10,11,18 When analyzing polymer conjugates, the IC50 values were
calculated based on the concentration of the small-molecule inhibitors. In investigating the
effect of the inhibitors' presence for the complete viral cycle (denoted herein as “In Agar”),
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equal concentrations of inhibitors were used for both pre-incubation with the virus and in the
nutrient agar overlay.18
Results and Discussion
Syntheses
To covalently attach multiple copies of amantadine (1) and rimantadine (2) to polymeric
chains without chemically modifying their amine moieties (revealed by protein X-ray
crystallography to be oriented toward interior of the virion upon binding6 and hence
presumably important), we sought structural analogs of 1 and 2 with readily functionalizable
groups on the opposite side of the molecules. Since commercially available 3-amino-1-
adamantanecarboxylic acid (3) and 3-(1-aminoethyl)adamantan-1-ol (7) fit this description,
we employed them as starting points.
Both 3 and 7 were first derivatized for polymer attachment through a series of chemical
reactions depicted in Figures 2 and 3. Since our previous studies (albeit with another
influenza inhibitor) demonstrated the benefits of a linker (spacer arm) between the drug and
the polymeric backbone in reducing steric hindrances,18 we also decided to insert a linker
between 3 or 7 and the polymers used. As seen in Figs. 2 and 3, first the drugs' amino groups
were protected by Fmoc and Boc groups, respectively, followed by linker attachment and
amine deprotection to afford 1 and 2 with azide terminating linkers to be subsequently used
for conjugation to polymers. Our initial studies herein utilized poly-L-glutamate as a
polymer because it is benign, freely water-soluble, biodegradable, and non-immunogenic.10
Amantadine (1) and its polymer conjugates
To verify which strains were resistant to the adamantane class of inhibitors, we determined
the IC50 values for monomeric 1 against three representative influenza strains using the
plaque reduction assay. They were A/Wuhan/359/95 (herein denoted as “Wuhan”), a human
strain with no known resistance to the adamantane class of influenza inhibitors; A/PR/8/34
(herein denoted as “PR8”), a human strain with documented resistance to the
adamantanes;21 and A/WSN/33 (herein denoted as “WSN”), a laboratory-adapted human
strain also with known resistance to the adamantanes.21 As seen in the 1st line of Table 1
(the first three data columns), the non-resistant Wuhan strain was indeed quite sensitive to 1
with an IC50 of 60 ± 24 μM. In contrast, the drug-resistant PR8 and WSN strains were both
far less sensitive toward the inhibitor with much poorer IC50 values of 2.2 ± 0.66 mM and
3.4 ± 0.2 mM, respectively, thus illustrating why 1 is no longer recommended for
therapeutic use.
When 6 was attached to poly-L-glutamate at a ∼7% loading (i.e., ∼7% of all the monomeric
units on the polymeric chain were drug-decorated), the inhibition for the resultant compound
13 (Figure 4) was nearly the same for the Wuhan and PR8 strains; for WSN, however, 13
was some 4-fold better inhibitor than 1 (Table 1, the first three data columns). When the
degree of loading was roughly doubled (to yield compound 14 in Fig. 4), the inhibition for
both the PR8 and WSN strains improved a few fold. Note that the original 1′s precursor 3
could not be tested as a monomer in the plaque reduction assay to determine the effect of
adding a –COOH to the structure because of its poor solubility in aqueous PBS, which is the
medium used in our antiviral assays.
We then investigated whether a further improvement in anti-influenza potency of the
polymer conjugates 13 and 14 over the monomeric 1 could be attained by lengthening the
time of their contact with the viruses during the assay. In our standard plaque reduction
assay (designated as “Not in Agar” in Table 1), compounds are incubated with the viruses
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for 1 h prior to infection and during the subsequent 1-h infection period. After that, the
inhibitors are removed, and fresh nutrient agar replaces them for the duration of the assay
(while plaque formation occurs). Therefore, in the next series of experiments, we decided to
keep the inhibitors present not only during those initial steps of the assay but also in an equal
concentration in the nutrient agar overlay to allow them to act on all subsequent steps in the
viral cycle.
As seen in Table 1 (the “In Agar” data columns), including the inhibitor for the entire plaque
reduction assay improved IC50 values in most instances. With 13 and 14, we observed no
improvement in IC50 values over 1 for the Wuhan strain but several-fold improvements for
the PR8 and WSN strains. Thus although the inclusion in the agar results in net lower IC50
values for most of the compounds tested, a greater magnitude of the improvement over the
monomer (1) was seen when polymer conjugates were present only at initial steps of viral
infection. Overall, however, these data show a marginal recovery in inhibitory potency
toward drug-resistant strains when multiple copies of 1 are attached to poly-L-glutamate.
Rimantadine (2) and its polymer conjugates
We next explored how the other FDA-approved M2 ion channel inhibitor, 2, as well as its
multiple copies attached to poly-L-glutamate, behaved against the aforementioned influenza
strains. As in the case of 1, the Wuhan strain was very sensitive to 2 with an even better IC50
value of 2.7 ± 1.4 μM, while both the PR8 and WSN strains were far less sensitive with
IC50s well into the low-single-millimolar range (Table 2), again confirming the reported
drug resistance patterns.21 We then tested the effect of the insertion of an OH group into 2′s
scaffold (to yield 7, which was used in subsequent derivatization (Fig. 3)). This small group
greatly diminished the inhibitory potency against the Wuhan strain raising the IC50 some
∼90-fold (Table 2, first data column, 2nd line). The addition of an OH group also
deleteriously, albeit less drastically, affected the already sub-optimal inhibition for the
resistant strains (Table 2, second and third data columns, 2nd line). Previous studies have
also demonstrated that the addition of a linker group to a small-molecule inhibitor can
negatively affect its inhibitory potency.10,18 (This decline can be overcome, however,
though multivalency.) That even a small addition, such as an OH group, has this deleterious
effect demonstrates how subtle the structure-activity relationship is in this case.
Covalent attachment of 11 to poly-L-glutamate at a ∼10% loading (compound 15, Fig. 4)
afforded a significant improvement for all three viral strains over 7 (Table 2, the first three
data columns, 3rd line). When compared to the native inhibitor (2), however, the polymer
conjugation did not fully overcome the negative effects of the OH for the Wuhan strain
leaving the IC50 value at 24 ± 5 μM, i.e., some 10-fold inferior to 2′s. The attachment to
poly-L-glutamate at a ∼10% loading did little for the inhibitory effect against the PR8 strain
but improved the IC50 for WSN some 4-fold over 2.
Effect of the degree of loading on rimantadine-polymer conjugates
Since our initial studies with 1 yielded an improvement when the loading of the inhibitor on
the polymeric chain was increased (Table 1), we explored whether 2 also followed this
trend. As seen in Table 2 (4th line, the first three data columns), increasing the loading to
∼20% (compound 16, Fig. 4) afforded some of the most potent poly-L-glutamate
conjugates: although the IC50 for 16 was still 10-fold worse than 2′s for the Wuhan strain,
for PR8 and WSN we saw 8-fold and 30-fold improvements over 2, respectively.
Interestingly, further increasing the degree of loading to ∼30% and then to ∼43%
(compounds 17 and 18, respectively, Fig. 4) gave little additional improvement or even
yielded worse inhibitors (Table 2).
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When testing the polymeric inhibitors 15, 16, 17, and 18 for the duration of the plaque
reduction assay (Table 2, the “In Agar” columns), patterns similar to those in the
experiments with 1 were observed: the net IC50 was improved in most cases, but the
magnitude of improvement over the monomer (2) became smaller. The optimal degree of
loading also became less clear for the PR8 strain because all compounds had nearly the same
IC50 values.
Effect of linker's properties on rimantadine-polymer conjugates
We next determined whether a slightly longer and more hydrophilic spacer arm between 2
and poly-L-glutamate would be of benefit. Figure 3 depicts the synthetic route to compound
12 which contains a hydrophilic, poly(ethylene glycol), linker and six extra atoms between
the drug and the polymeric chain. As seen in Table 2, when 12 is attached to poly-L-
glutamate at a ∼10% loading to generate compound 19 (Fig. 4), there was little or no
improvement in inhibition over 2 (some 70-fold worse for the Wuhan strain, no change for
PR8, and approximately a 3-fold improvement for WSN). When the loading was increased
to ∼20% (compound 20), which was optimal for the shorter and more hydrophobic linker,
the inhibition was improved compared to 19: only a 18-fold worse inhibition for the Wuhan
strain and a 13-fold improvements for both PR8 and WSN over 2 (Table 2).
When assaying 19 and 20 for the duration of the assay (Table 2, “In Agar”), no sizable
benefit to the longer incubation was observed again and, in fact, 19 exhibited toxic effects in
this modality. Since the slightly longer and more hydrophilic linker failed to generate major
improvements compared to the shorter and more hydrophobic one, we decided to continue
our studies with the latter.
Effect of polymer's structure on rimantadine-polymer conjugates
To determine whether increasing hydrophobicity of the polymeric backbone by inserting
extra aromatic or aliphatic hydrophobic moieties into it would improve inhibition, perhaps
due to extra interactions between the polymer and the viral surface,12 we synthesized 21
containing ∼20% of benzyl rings in addition to a ∼15% loading of 2, as well as 22
containing ∼25% of tert-butyl substituents in addition to ∼20% of 2 moieties (Fig. 5). When
conjugate 21 was tested against all three influenza strains in the plaque reduction assay, we
observed similar improvements over 2 compared to that afforded by poly-L-glutamate with
∼20% loading and no additional hydrophobic moieties (16) for the Wuhan and PR8 strains,
and not as marked improvements for the WSN strain: some 18-fold weaker inhibition than
the monomer for the Wuhan strain and 16/17-fold improvements for WSN and PR8 (Table
2). Similarly, for the tert-butyl-derivatized poly-L-glutamate conjugate 22, we saw the same
18-fold decline in improvement over 2 for the Wuhan strain and some 10- and 22-fold
improvements over 2 for PR8 and WSN, respectively. Therefore, although the addition of
hydrophobic groups to the polymer in some cases did lead to a modest improvement over
the 20%-derivatized plain poly-L-glutamate, there was no compelling reason for their
inclusion.
We also examined the role of polymer's characteristics in the conjugate's inhibitory potency.
To this end, first the charge of the poly-L-glutamate backbone was abolished by
transforming it into the neutral poly-L-glutamine (compound 23, Fig. 6). As seen in Table 2,
the neutralization of the polymer resulted in no improvements and actually in over 20-fold
weaker inhibition than with the monomeric 2 for the Wuhan strain. For PR8 and WSN, 23
afforded 2- and 12-fold improvements, respectively, over 2, which is worse than 23′s
negatively charged counterpart, 16. When incubated with the viruses for the duration of the
assay, 23 exhibited improvements over the monomer for the PR8 and WSN strains, but not
marked ones (Table 2, “In Agar”). Thus, putative electrostatic repulsions between the virus
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and polymer are not a significant factor in viral inhibition for our system (in contrast to
observations in previous studies10,12); also, the neutralization of the poly-L-glutamate
backbone to form poly-L-glutamine generated less potent inhibitors for drug-polymer
conjugates at the same degree of small-molecule loading.
To investigate how new, structurally unrelated polymeric backbones would affect the
inhibition of drug-resistant influenza viruses by polymer-conjugated 2, the dissimilar
polymers poly(acrylic acid Na salt) and carboxymethylcellulose Na salt (CMC) were
employed. Since each of these polymers, like poly-L-glutamate, contained carboxylate
moieties, the same conjugation chemistry could be carried out.
Polyacrylate with ∼10% of its monomeric units derivatized with 2 (compound 24, Fig. 6)
was superior to all other conjugates tested against the Wuhan strain: it overcame all negative
effects from an OH addition to 2 with an IC50 equal to that of the commercial drug itself
(Table 2). However, against the other two influenza strains 24 did not possess the same
potency with IC50 values of 120 ± 50 and 280 ± 50 μM for PR8 and WSN, thus resulting in
some 11- and 8-fold improvements, respectively, over 2 for these drug-resistant strains
(Table 2). Compound 24 was, however, markedly better than other 10%-modified polymer-
conjugates (15 and 19), suggesting that the polyacrylate backbone is a promising lead for
multivalent inhibitors.12,13
Attachment of 2 to CMC at a ∼20% loading (25, Fig. 6) drastically curtailed inhibition of
the Wuhan strain, with an IC50 of 760 ± 160 μM (Table 2). Similarly poor IC50 values were
obtained against PR8 and WSN (1,200 ± 800 and 780 ± 90 μM, respectively) suggesting
that the inhibition afforded by these compounds might not even be caused by 2′s action per
se but be due to CMC's intrinsic weak antiviral activity.
In closing, in this study we have attached multiple copies of influenza M2 ion-channel
inhibitors to a variety of polymers in an attempt to ameliorate, if not salvage, their ability to
inhibit adamantane-resistant influenza strains. Our previous studies have shown that for
another influenza virus inhibitor, zanamivir, polymer conjugation to form multivalent
inhibitors could completely overcome resistance in zanamivir-resistant strains.10 However,
zanamivir binds to its target neuraminidase on the outermost solvent-exposed portion of the
enzyme2,22 which is presumably readily accessed to the drug-polymer conjugate. In contrast,
the M2 ion channel imbedded within the viral membrane could be more difficult to access,
thereby hindering multivalency. Additionally, the neuraminidase's greater abundance on the
viral surface (about 100 copies per virion compared to some 20 copies for the M2 ion
channel)22 may also play a role in our incomplete potency recovery. Nonetheless, a progress
toward our goal of recovering the adamantane inhibitors has been made by preparing 2-
polymer conjugates up to 30-fold more potent than their monomeric precursors against some
drug-resistant influenza strains.
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Figure 1.
Chemical structures of both FDA-approved adamantane-class M2 ion channel influenza A
inhibitors still in therapeutic use: amantadine·HCl (1) and rimantadine·HCl (2).
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Figure 2.
Synthetic route to generating the 1-linker-azide compound 6 for subsequent covalent
attachment to poly-L-glutamate. Reagents employed: (a) Fmoc-Cl, Na2CO3, H2O/acetone;
(b) HBTU, 5-azidopentan-1-amine, Hünig's base, THF; and (c) anhydrous acetonitrile/
diethylamine. See Methods for details.
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Figure 3.
Synthetic route to generating the 2-linker-azide compounds 11 and 12 for subsequent
covalent attachment to poly-L-glutamate and other polymers. Reagents employed: (a) di-
tert-butyl dicarbonate, dichloromethane; (b) 5-azido-pentanoic acid or 11-azido-3,6,9-
trioxaundecanoic acid, DPTC, DMAP, chlorobenzene (reflux); (c) 4 M HCl in dioxane. See
Methods for details.
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Figure 4.
Chemical structures of poly-L-glutamate-attached conjugates of 1 and 2 at various degrees
of loading (% of derivatization).
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Figure 5.
Chemical structures of poly-L-glutamate derivatized with ∼15% of 2 of plus ∼20% of
benzylamine (21) and with ∼20% of 2 plus ∼25% of 2,2-dimethyl-1-propamine (22).
Larson et al. Page 15
J Pharm Sci. Author manuscript; available in PMC 2014 August 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
Chemical structures of poly-L glutamine, poly(acrylic acid Na salt), and CMC derivatized
with 2.
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